CO2023006647A2 - Compuestos moduladores del cftr, composiciones y usos de estos - Google Patents
Compuestos moduladores del cftr, composiciones y usos de estosInfo
- Publication number
- CO2023006647A2 CO2023006647A2 CONC2023/0006647A CO2023006647A CO2023006647A2 CO 2023006647 A2 CO2023006647 A2 CO 2023006647A2 CO 2023006647 A CO2023006647 A CO 2023006647A CO 2023006647 A2 CO2023006647 A2 CO 2023006647A2
- Authority
- CO
- Colombia
- Prior art keywords
- compounds
- compositions
- methods
- cftr
- modulating compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063104979P | 2020-10-23 | 2020-10-23 | |
| PCT/IB2021/000710 WO2022084741A1 (en) | 2020-10-23 | 2021-10-22 | Cftr modulator compounds, compositions, and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2023006647A2 true CO2023006647A2 (es) | 2023-05-29 |
Family
ID=81290147
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2023/0006647A CO2023006647A2 (es) | 2020-10-23 | 2023-05-19 | Compuestos moduladores del cftr, composiciones y usos de estos |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11827640B2 (enExample) |
| EP (1) | EP4232451A4 (enExample) |
| JP (1) | JP2023547389A (enExample) |
| KR (1) | KR20230096026A (enExample) |
| CN (1) | CN116348468A (enExample) |
| AR (1) | AR123884A1 (enExample) |
| AU (1) | AU2021363703A1 (enExample) |
| CA (1) | CA3196061A1 (enExample) |
| CL (1) | CL2023001139A1 (enExample) |
| CO (1) | CO2023006647A2 (enExample) |
| IL (1) | IL302247A (enExample) |
| MX (1) | MX2023004712A (enExample) |
| PY (1) | PY2193067A (enExample) |
| TW (1) | TW202233620A (enExample) |
| UY (1) | UY39482A (enExample) |
| WO (1) | WO2022084741A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114380835B (zh) * | 2022-01-06 | 2022-12-27 | 南京桦冠生物技术有限公司 | 一种7-(3,4-二甲氧苯基)-2-吡唑[1,5-a]嘧啶羧酸的制备方法 |
| TW202425990A (zh) * | 2022-11-02 | 2024-07-01 | 南韓商日東製藥股份有限公司 | 包含ｃｆｔｒ調節劑化合物之點眼用組成物 |
| CN120097921A (zh) * | 2024-07-05 | 2025-06-06 | 广东省科学院动物研究所 | 二氟甲氧基苯基类pde4抑制剂及其应用 |
| CN121609673A (zh) * | 2026-02-02 | 2026-03-06 | 五邑大学 | 一种pde4抑制剂及其制备方法和应用 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4178449A (en) | 1978-04-17 | 1979-12-11 | American Cyanamid Company | Pyrazolo[1,5-a]pyrimidines and imidazo-[1,5-a]pyrimidines |
| US4281000A (en) | 1979-07-09 | 1981-07-28 | American Cyanamid Company | Substituted pyrazolo (1,5-a)pyrimidines and their use as anxiolytic agents |
| AU651986B2 (en) | 1991-04-22 | 1994-08-11 | Otsuka Pharmaceutical Factory, Inc. | Pyrazolo{1,5-a}pyrimidine derivative and anti-inflammatory containing the same |
| CA2465326C (en) * | 2001-11-01 | 2011-03-29 | Icagen, Inc. | Pyrazolopyrimidines for decreasing ion flow through a voltage-dependent sodium channel |
| AU2003240488A1 (en) | 2002-06-04 | 2003-12-19 | Neogenesis Pharmaceuticals, Inc. | Pyrazolo` 1,5a! pyrimidine compounds as antiviral agents |
| US7449488B2 (en) * | 2002-06-04 | 2008-11-11 | Schering Corporation | Pyrazolopyrimidines as protein kinase inhibitors |
| JP2004170323A (ja) | 2002-11-22 | 2004-06-17 | Sumitomo Pharmaceut Co Ltd | 皮膚疾患治療剤のスクリーニング方法 |
| WO2004087153A2 (en) | 2003-03-28 | 2004-10-14 | Chiron Corporation | Use of organic compounds for immunopotentiation |
| WO2004089471A2 (en) | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | NEW PYRAZOLO[1,5-a] PYRIMIDINES DERIVATIVES AND PHARMACEUTICAL USE THEREOF |
| US20070270408A1 (en) | 2003-04-11 | 2007-11-22 | Novo Nordisk A/S | Pharmaceutical use of substituted pyrazolo[1,5-a]pyrimidines |
| WO2004089416A2 (en) | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | Combination of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent |
| WO2005037837A1 (ja) | 2003-10-17 | 2005-04-28 | Nippon Kayaku Kabushiki Kaisha | 置換２−アミノ−[１，２，４]トリアゾロ[１，５−a]ピリミジン誘導体及びその用途 |
| US7498434B2 (en) | 2004-01-14 | 2009-03-03 | Mallinckrodt Inc | Two-phase method for the synthesis of selected pyrazolopyrimidines |
| EP1778685B1 (de) | 2004-08-02 | 2008-03-26 | Schwarz Pharma Ag | Carboxamide des indolizins und seiner aza- und diazaderivate |
| WO2006088246A1 (ja) | 2005-02-18 | 2006-08-24 | Takeda Pharmaceutical Company Limited | Ｇｐｒ３４受容体機能調節剤 |
| AR056876A1 (es) | 2005-10-21 | 2007-10-31 | Tanabe Seiyaku Co | Compuestos de pirazolo[1-5-a]pirimidina, antagonistas de receptores canabinoides cb1, composiciones farmaceuticas que los contienen y usos en el tratamiento de enfermedades del sistema nervioso central, tales como trastornos psicoticos, neurologicos y similares |
| AR061793A1 (es) | 2006-07-05 | 2008-09-24 | Mitsubishi Tanabe Pharma Corp | Compuesto de pirazolo[1,5-a] pirimidina y composicion farmaceutica |
| WO2008045664A2 (en) | 2006-10-06 | 2008-04-17 | Kalypsys, Inc. | Heterocyclic pde4 inhibitors as antiinflammatory agents |
| WO2008056176A1 (en) | 2006-11-10 | 2008-05-15 | Scottish Biomedical Limited | Pyrazolopyrimidines as phosphodiesterase inhibitors |
| CA2705303A1 (en) * | 2007-11-07 | 2009-05-14 | Foldrx Pharmaceuticals, Inc. | Modulation of protein trafficking |
| JP5637859B2 (ja) * | 2007-12-13 | 2014-12-10 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | 嚢胞性線維症膜コンダクタンスレギュレーターのモジュレーター |
| WO2010063487A1 (en) | 2008-12-05 | 2010-06-10 | Merz Pharma Gmbh & Co. Kgaa | Pyrazolopyrimidines, a process for their preparation and their use as medicine |
| JP5578490B2 (ja) | 2008-12-26 | 2014-08-27 | 味の素株式会社 | ピラゾロピリミジン化合物 |
| WO2010086040A1 (en) | 2009-01-29 | 2010-08-05 | Biomarin Iga, Ltd. | Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy |
| WO2011050245A1 (en) | 2009-10-23 | 2011-04-28 | Yangbo Feng | Bicyclic heteroaryls as kinase inhibitors |
| EP2588105A1 (en) | 2010-07-01 | 2013-05-08 | Cellzome Limited | Triazolopyridines as tyk2 inhibitors |
| US8883789B2 (en) * | 2011-12-14 | 2014-11-11 | Boehringer Ingelheim International Gmbh | Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors |
| EP2831074B1 (en) | 2012-03-29 | 2016-09-14 | Boehringer Ingelheim International GmbH | Novel pyrazolopyrimidines as metabotropic glutamate 5 receptor antagonists for the treatment of psychiatric diseases |
| WO2014144455A1 (en) | 2013-03-15 | 2014-09-18 | Epizyme, Inc. | 1 -phenoxy-3-(alkylamino)-propan-2-ol derivatives as carm1 inhibitors and uses thereof |
| CN103923105B (zh) | 2014-04-17 | 2016-08-24 | 北京大学 | 2-中氮茚甲酰胺类化合物及其制备和用途 |
| WO2016012896A1 (en) * | 2014-07-24 | 2016-01-28 | Pfizer Inc. | Pyrazolopyrimidine compounds |
| JP2018076234A (ja) | 2015-03-16 | 2018-05-17 | 大正製薬株式会社 | ピラゾロ［１，５−ａ］ピリミジン化合物 |
| JP6894902B2 (ja) | 2015-12-24 | 2021-06-30 | ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア | Ｃｆｔｒ制御因子及びこの使用方法 |
| CN107286156A (zh) | 2016-04-05 | 2017-10-24 | 江苏新元素医药科技有限公司 | 新型urat1抑制剂及其在医药上的应用 |
| WO2018078005A1 (en) | 2016-10-29 | 2018-05-03 | Bayer Pharma Aktiengesellschaft | Amido-substituted azaspiro derivatives as tankyrase inhibitors |
| JP2020514323A (ja) | 2017-02-06 | 2020-05-21 | ケース ウエスタン リザーブ ユニバーシティ | 短鎖デヒドロゲナーゼ活性を調節する組成物と方法 |
| WO2018226150A1 (en) | 2017-06-05 | 2018-12-13 | Medivir Aktiebolag | Pyrazolopyrimidine as malt-1 inhibitors |
-
2021
- 2021-10-22 AU AU2021363703A patent/AU2021363703A1/en active Pending
- 2021-10-22 IL IL302247A patent/IL302247A/en unknown
- 2021-10-22 AR ARP210102922A patent/AR123884A1/es not_active Application Discontinuation
- 2021-10-22 CN CN202180072298.5A patent/CN116348468A/zh active Pending
- 2021-10-22 EP EP21882228.6A patent/EP4232451A4/en active Pending
- 2021-10-22 TW TW110139341A patent/TW202233620A/zh unknown
- 2021-10-22 MX MX2023004712A patent/MX2023004712A/es unknown
- 2021-10-22 JP JP2023524685A patent/JP2023547389A/ja active Pending
- 2021-10-22 WO PCT/IB2021/000710 patent/WO2022084741A1/en not_active Ceased
- 2021-10-22 CA CA3196061A patent/CA3196061A1/en active Pending
- 2021-10-22 PY PY202102193067A patent/PY2193067A/es unknown
- 2021-10-22 KR KR1020237017551A patent/KR20230096026A/ko active Pending
- 2021-10-22 US US17/508,198 patent/US11827640B2/en active Active
- 2021-10-22 UY UY0001039482A patent/UY39482A/es unknown
-
2023
- 2023-04-20 CL CL2023001139A patent/CL2023001139A1/es unknown
- 2023-05-19 CO CONC2023/0006647A patent/CO2023006647A2/es unknown
- 2023-10-17 US US18/488,925 patent/US20240199623A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| TW202233620A (zh) | 2022-09-01 |
| MX2023004712A (es) | 2023-05-09 |
| AU2021363703A9 (en) | 2025-01-09 |
| US20230080486A1 (en) | 2023-03-16 |
| JP2023547389A (ja) | 2023-11-10 |
| KR20230096026A (ko) | 2023-06-29 |
| CN116348468A (zh) | 2023-06-27 |
| IL302247A (en) | 2023-06-01 |
| UY39482A (es) | 2022-05-31 |
| US20240199623A1 (en) | 2024-06-20 |
| AR123884A1 (es) | 2023-01-18 |
| CA3196061A1 (en) | 2022-04-28 |
| PY2193067A (es) | 2022-06-20 |
| WO2022084741A1 (en) | 2022-04-28 |
| EP4232451A1 (en) | 2023-08-30 |
| EP4232451A4 (en) | 2024-11-06 |
| US11827640B2 (en) | 2023-11-28 |
| AU2021363703A1 (en) | 2023-06-22 |
| CL2023001139A1 (es) | 2023-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2023006647A2 (es) | Compuestos moduladores del cftr, composiciones y usos de estos | |
| CL2020002146A1 (es) | Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer. | |
| ECSP22087539A (es) | Inhibidores de kras tricíclicos fusionados | |
| CO2021008018A2 (es) | Composiciones y métodos para modular la actividad de deshidrogenasas de cadena corta | |
| CL2021002882A1 (es) | Inhibidores de fgfr y métodos de uso de los mismos | |
| NI202000085A (es) | Moduladores de la expresión de apol1 | |
| MX389700B (es) | Derivados de pirazolopiridina como moduladores de cinasa 1 progenitora hematopoyetica (hpk1) y usos de los mismos para tratamiento de cancer. | |
| MX2022003166A (es) | Moduladores de il-17a y usos de los mismos. | |
| BR112021006392A2 (pt) | moduladores da alfa-1 antitripsina | |
| CL2020001349A1 (es) | Compuestos, composición y uso de los mismos como moduladores de la expresión de pcsk9. (divisional solicitud 201902574) | |
| CR20240267A (es) | Moduladores de la expresión de pnpla3 (divisional exp. 2021-0180) | |
| MX2023001236A (es) | Inhibidores de cinasa inducibles por sal. | |
| CO2018013077A2 (es) | Inhibidores de la arginasa y sus aplicaciones terapéuticas | |
| ES2959399T3 (es) | Aminopirrolotriazinas como inhibidores de cinasa | |
| CO2021009009A2 (es) | Moduladores de la expresión de hsd17b13 | |
| MX2022014924A (es) | Moduladores de il-17a. | |
| CL2021001461A1 (es) | Moduladores de trex1 | |
| CO2020008769A2 (es) | Moduladores de la expresión dnm2 | |
| MX2020009147A (es) | Moduladores de la expresion de irf4. | |
| CL2024003731A1 (es) | Compuestos tricíclicos de triazolo, inhibidores de dgk; uso para tratar cáncer. | |
| MX2022012366A (es) | Metodos para generar neuronas de dopamina del mesencefalo, neuronas del mesencefalo, y usos de las mismas. | |
| MX2024010648A (es) | Inhibidores de diacilglicerol cinasa (dgk) alfa y usos de los mismos | |
| CL2023001637A1 (es) | Inhibidores de la vía jak1 para el tratamiento del vitíligo. | |
| UY40457A (es) | Inhibidores de tead y métodos de uso de los mismos | |
| CL2022002684A1 (es) | Composiciones de anticuerpo anti-cd6 y métodos para tratar y reducir efectos negativos de un coronavirus |